Byrne Financial Freedom’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$463K Sell
3,627
-74
-2% -$9.24K 0.22% 62
2025
Q4
$451K Buy
3,701
+462
+14% +$53K 0.21% 64
2025
Q3
$325K Sell
3,239
-953
-23% -$85.8K 0.16% 74
2025
Q2
$348K Sell
4,192
-375
-8% -$29.9K 0.17% 72
2025
Q1
$370K Hold
4,567
0.21% 62
2024
Q4
$411K Buy
+4,567
New +$442K 0.18% 60

Other funds holding XBI

Byrne Financial Freedom's XBI Position: Q1 2026 in Review

Byrne Financial Freedom reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 2% in Q1 2026, selling an estimated $9.24K and leaving 3,627 shares worth $463K. The position accounts for 0.22% of the portfolio, ranked #62.

Byrne Financial Freedom first reported a position in XBI in Q4 2024 and has held it in 6 quarters since. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Byrne Financial Freedom held 3,627 shares of State Street SPDR S&P Biotech ETF worth $463K as of Q1 2026.
  • Byrne Financial Freedom sold 74 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $9.24K.
  • State Street SPDR S&P Biotech ETF made up 0.22% of Byrne Financial Freedom's portfolio in Q1 2026, its #62 holding.
  • Byrne Financial Freedom first reported a position in State Street SPDR S&P Biotech ETF in Q4 2024 and has held it in 6 quarters since.
  • 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Byrne Financial Freedom's 13F filing for Q1 2026, filed 27 Apr 2026.